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abstract
Proton pump inhibitors (PPIs) are widely used in the management of upper gastrointestinal disorders. In recent years, concerns 
have been raised on the potential adverse effects of long-term PPI use. This article reviews the published evidence of the effect 
of long-term PPI use on the absorption of minerals and vitamins, risk of infections, chronic kidney disease and dementia.
iNtroductioN
Proton pump inhibitors (PPIs) are amongst the most 
commonly prescribed drugs globally, widely used for 
the prevention and treatment of acid-related disorders 
such as gastroesophageal reflux disease and peptic ulcer 
disease. Studies have however, shown that PPIs are often 
overprescribed	or	used	inappropriately,	with	25%	-	70%	of	
patients taking these drugs without having an appropriate 
indication.1 Although PPIs are well tolerated and have been 
approved for long-term use, concern and evidence on the 
potential long-term adverse effects are increasingly emerging. 
This article reviews published information on adverse effects 
associated with long-term PPI use.
absorptioN oF vitamiNs aNd miNErals
PPIs block the hydrogen-potassium adenosine triphosphatase 
enzyme system of the gastric parietal cell, leading to inhibition 
of gastric acid secretion. This in turn, can lead to decreased 
absorption of minerals such as calcium, magnesium and iron as 
well as vitamins such as vitamin B12.
Gastric acid suppression by PPIs has been postulated to 
result in altered calcium metabolism, causing low bone density 
and an increased risk of fractures. The mechanism is related 
to both decreased absorption of calcium compounds in the 
presence of achlorhydria and primary hyperparathyroidism. 
The latter results from parathyroid hyperplasia secondary to 
the hypergastrinaemia caused by profound acid suppression.2 
Several studies have investigated the association of PPIs to 
fracture risk; however the results have been inconsistent. 
The latest meta-analysis of observational studies, published 
in 2016, has shown that PPI use modestly increased the risk 
of hip, spine, and any-site fracture, but with no evidence of 
duration effect in subgroup analysis.3 Thus, in patients with 
increased risk of bone fractures, caution should be exercised 
when prescribing long term PPIs. Adequate dietary calcium 
intake with vitamin D and calcium supplementation should be 
considered, ideally in forms that are not influenced by gastric 
acid for absorption, such as calcium citrate.2,4
Iron and vitamin B12 absorption can be hindered by the 
low gastric acid levels produced by PPIs. Dietary iron is present 
in	food	as	non-haem	(66%)	or	haem	iron	(32%).	Gastric	acid	
assists food sources containing non-haem iron to dissociate and 
to solubilize the iron salts. These salts can then form complexes 
with sugars and amines, facilitating absorption.5 The data on 
the effect of PPIs on iron absorption is inconsistent. There are 
case reports showing iron deficiency anaemia which resolved 
when PPI therapy was stopped6 and a retrospective cohort 
study showing a significant decrease in haemoglobin in PPI 
users.7 Patients with hereditary haemochromatosis were shown 
to require less frequent phlebotomies when given PPIs.8 On 
the other hand, two small studies did not show any significant 
change in iron levels in patients on short or long-term PPIs9,10 
whilst a cohort of patients with Zollinger-Ellison Syndrome 
who received treatment with PPIs for over 10 years did not 
demonstrate a clinically significant iron deficiency.11 As yet, 
there are no recommendations to monitor patients on long-term 
PPI therapy for iron deficiency anaemia and patients shown to 
be anaemic should be investigated as per published guidelines.
Vitamin B12 is a protein-bound vitamin that requires the 
presence of gastric acid and pepsin for it to be released in the 
stomach.12 Once again, studies have shown conflicting data with a 
recent, large, case-control study showing that the use of PPIs for two 
years or more was significantly associated with a new diagnosis of 
vitamin B12 deficiency.13 On the other hand, a cross-sectional study 
failed to show a significant difference in serum B12 levels in patients 
on PPIs, compared to their partners who were not on PPIs14. In a 
systematic review, the authors concluded that PPI therapy does not 
statistically affect the absorption of vitamin B12.5
6 Volume 16, 2017  Issue 04
In	2011,	the	FDA	released	a	warning	that	long-term	PPI	
use may cause hypomagnesaemia, including clinically serious 
adverse events. In approximately one-quarter of the cases 
reviewed, magnesium supplementation did not improve the low 
magnesium level and the PPI had to be discontinued. Whilst the 
true incidence of PPI-induced hypomagnesaemia is unknown, 
FDA	recommends	checking	magnesium	levels	periodically	in	
patients expected to be on prolonged PPI treatment or who take 
PPIs with other medications that may cause hypomagnesemia 
(such as diuretics) or digoxin.4
iNFEctioNs
Gastric acid secretion is part of the local defence system 
against orally ingested pathogens and its suppression could, 
theoretically, lead to an increased risk of enteric infections. In 
addition, a twin study has shown a significant impact of PPIs on 
the gut microbiome.15
Infection with Clostridium difficile is of particular importance 
due to its morbidity. A meta-analysis of 42 observational studies 
has shown a probable association between PPI use and incident 
and recurrent Clostridium difficile infection.16 This resulted in 
the	FDA	issuing	a	safety	announcement	on	the	increased	risk	in	
PPI users of Clostridium difficile-associated diarrhoea, especially 
in elderly patients with chronic underlying medical conditions 
or on broad spectrum antibiotics.4 A systematic review has also 
shown that PPI use increases patient susceptibility to other enteric 
infections such as Salmonella, Campylobacter jejuni and small 
intestinal bacterial overgrowth.17
Long-term PPI treatment has also been linked to 
pneumonia. The mechanism with this association may be 
due to upper gastrointestinal bacterial overgrowth, resulting 
in an increased susceptibility to respiratory infections by 
potential micro-aspiration or translocation into the lungs. Data 
is inconsistent, with some recent meta-analyses suggesting 
that PPI use is associated with an increased risk of both 
community and hospital-acquired pneumonia18 and others 
failing to show an association.19
rENal disEasE
Over the years, concerns have been raised about the adverse 
renal effects of PPIs, with acute interstitial nephritis being the 
most frequently observed acute kidney damage in PPI users. The 
proposed mechanism is thought to be secondary to deposition 
of PPIs or their metabolites in the kidney’s tubulo-interstitium 
compartment and direct stimulation of an immune response.20 
Three large population-based studies in Canada, the United 
States and New Zealand have all shown a higher risk of acute 
interstitial nephritis in patients on PPIs compared to controls. 
In some cases, this acute injury goes unrecognized and therefore 
uncorrected. While most patients recover kidney function, many 
are left with some level of chronic kidney injury.12,20 Several 
studies have shown an association of PPI use with chronic 
kidney disease.21 Caution should therefore be exercised when 
prescribing PPIs to patients who have other risk factors for renal 
disease and patients on long-term treatment should have their 
renal function monitored.
dEmENtia
PPIs were shown to lead to higher levels of amyloid-beta in 
the brains of mice in a manner similar to the extracellular 
deposition of amyloid-beta peptides seen in the pathogenesis of 
Alzheimer’s disease. This lead to the hypothesis that PPI use can 
be associated with an increased risk of dementia. A systematic 
review looking at 11 studies showed a positive association 
between PPI use and dementia (three out of four studies) or 
acute cognitive impairment; however, the authors pointed out 
several methodological problems and conflicting results.22	Further	
longitudinal studies are needed to confirm this association.
coNclusioN
Although PPIs are safe and effective drugs, their long-term use 
carries potential risks. As with all medications, there should be a 
clear indication when prescribing PPIs, with the lowest effective 
dose being used. It is recommended to weigh the benefits of PPI 
therapy against the risks, especially in patients with multiple co-
morbidities and in the elderly. As clinical situations may change 
over time, patients should be regularly reviewed as to whether 
acid suppression is still required. 
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The ability to write up research in a paper that can withstand peer-
review is a crucial and critical requisite for all academics, not only to 
disseminate their work, but also to further their careers. The skills 
required are manifold and are usually acquired piecemeal. WASP 
(Write a Scientific Paper) is an intensive and comprehensive 3-day 
course that covers all requisite paper-writing skills. 
Core subjects include: literature appraisal, proposals, ethics 
and data protection, seeking materials for publication, preparing 
a compelling abstract, an attractive poster and a captivating 
presentation, how to lay out a paper, which journals to target (and 
why), editors’ viewpoints, tackling editors, the difference between a 
paper and a thesis, and statistics. Almost a third of WASP includes 
statistical analysis using the familiar Microsoft Excel environment. 
The WASP faculty comprises experienced researchers and journal 
editors. WASP’s purpose is to impart the lecturers’ collective 
experience to the delegates in this crucial aspect of career progress.
WASP courses include soft copies of all talks, all papers 
discussed as examples, all spreadsheets including actual data 
research wasp (wrIte a scIentIfIc paper) 
agaIn In malta and londonvictor GrEch
used in published papers, as well as spreadsheets that extend 
Excel’s native capabilities. WASP also has a half day of statistics 
exercises using Microsoft Excel. The author is well suited to 
impart the statistics lectures, having co-written the statistics 
chapter in The Science of Paediatrics: MRCPCH Mastercourse.1 
WASP has been held in Malta almost annually since 2010. 
After each iteration, feedback has been used for fine-tuning 
WASP. The course was held in London, for the first time, at the 
Royal	College	of	Paediatrics	and	Child	Health	at	the	end	of	
January	2017.	This	is	a	unique	course	worldwide	and	feedback	
has been excellent (table 1). The modus operandi for WASP has 
also been published.2 
This event is suitable for all individuals in the sciences field 
who wish to enhance their paper writing skills by acquiring 
sound competences in academic writing. WASP will once again 
be held in Malta (2-4/10/2017) and in London (23-25/10/2017). 
The WASP faculty looks forward to meeting you. Registration is 
available at www.ithams.com/wasp. 
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